Logo image of ICCC

IMMUCELL CORP (ICCC) Stock Fundamental Analysis

NASDAQ:ICCC - Nasdaq - US4525253062 - Common Stock - Currency: USD

6.735  -0.01 (-0.22%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ICCC. ICCC was compared to 558 industry peers in the Biotechnology industry. The financial health of ICCC is average, but there are quite some concerns on its profitability. ICCC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ICCC has reported negative net income.
In the past year ICCC had a positive cash flow from operations.
ICCC had negative earnings in each of the past 5 years.
In multiple years ICCC reported negative operating cash flow during the last 5 years.
ICCC Yearly Net Income VS EBIT VS OCF VS FCFICCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

ICCC's Return On Assets of -0.60% is amongst the best of the industry. ICCC outperforms 89.43% of its industry peers.
With an excellent Return On Equity value of -0.94%, ICCC belongs to the best of the industry, outperforming 90.86% of the companies in the same industry.
Industry RankSector Rank
ROA -0.6%
ROE -0.94%
ROIC N/A
ROA(3y)-7.84%
ROA(5y)-5.24%
ROE(3y)-13.05%
ROE(5y)-8.6%
ROIC(3y)N/A
ROIC(5y)N/A
ICCC Yearly ROA, ROE, ROICICCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

The Gross Margin of ICCC (32.96%) is better than 74.37% of its industry peers.
In the last couple of years the Gross Margin of ICCC has declined.
The Profit Margin and Operating Margin are not available for ICCC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 32.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.67%
GM growth 5Y-9.41%
ICCC Yearly Profit, Operating, Gross MarginsICCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

ICCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ICCC has more shares outstanding than it did 1 year ago.
ICCC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ICCC has been reduced compared to a year ago.
ICCC Yearly Shares OutstandingICCC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ICCC Yearly Total Debt VS Total AssetsICCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

An Altman-Z score of 2.71 indicates that ICCC is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.71, ICCC is in the better half of the industry, outperforming 72.94% of the companies in the same industry.
The Debt to FCF ratio of ICCC is 12.89, which is on the high side as it means it would take ICCC, 12.89 years of fcf income to pay off all of its debts.
ICCC has a better Debt to FCF ratio (12.89) than 92.29% of its industry peers.
ICCC has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.30, ICCC is doing worse than 72.58% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF 12.89
Altman-Z 2.71
ROIC/WACCN/A
WACC9.26%
ICCC Yearly LT Debt VS Equity VS FCFICCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 4.12 indicates that ICCC has no problem at all paying its short term obligations.
ICCC has a Current ratio (4.12) which is in line with its industry peers.
A Quick Ratio of 2.21 indicates that ICCC has no problem at all paying its short term obligations.
With a Quick ratio value of 2.21, ICCC is not doing good in the industry: 71.51% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 4.12
Quick Ratio 2.21
ICCC Yearly Current Assets VS Current LiabilitesICCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 86.27% over the past year.
ICCC shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.28%.
ICCC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.07% yearly.
EPS 1Y (TTM)86.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%366.67%
Revenue 1Y (TTM)28.28%
Revenue growth 3Y11.25%
Revenue growth 5Y14.07%
Sales Q2Q%11.16%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ICCC Yearly Revenue VS EstimatesICCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ICCC Yearly EPS VS EstimatesICCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2023 2024 -0.2 -0.4 -0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ICCC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ICCC Price Earnings VS Forward Price EarningsICCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

ICCC's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ICCC is cheaper than 93.91% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ICCC is valued cheaply inside the industry as 91.94% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 77.18
EV/EBITDA 26.92
ICCC Per share dataICCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ICCC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUCELL CORP

NASDAQ:ICCC (6/5/2025, 3:20:23 PM)

6.735

-0.01 (-0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-11 2025-08-11
Inst Owners13.58%
Inst Owner Change1.61%
Ins Owners22.27%
Ins Owner Change0%
Market Cap60.88M
Analysts82.86
Price TargetN/A
Short Float %0.19%
Short Ratio0.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.23
P/FCF 77.18
P/OCF 40.24
P/B 2.1
P/tB 2.11
EV/EBITDA 26.92
EPS(TTM)-0.07
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.09
FCFY1.3%
OCF(TTM)0.17
OCFY2.49%
SpS3.02
BVpS3.21
TBVpS3.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.6%
ROE -0.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 32.96%
FCFM 2.89%
ROA(3y)-7.84%
ROA(5y)-5.24%
ROE(3y)-13.05%
ROE(5y)-8.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.67%
GM growth 5Y-9.41%
F-Score7
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF 12.89
Debt/EBITDA 3.5
Cap/Depr 26.87%
Cap/Sales 2.65%
Interest Coverage N/A
Cash Conversion 61.18%
Profit Quality N/A
Current Ratio 4.12
Quick Ratio 2.21
Altman-Z 2.71
F-Score7
WACC9.26%
ROIC/WACCN/A
Cap/Depr(3y)82.27%
Cap/Depr(5y)105.22%
Cap/Sales(3y)11.34%
Cap/Sales(5y)14.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%366.67%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)28.28%
Revenue growth 3Y11.25%
Revenue growth 5Y14.07%
Sales Q2Q%11.16%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y94.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y108.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y130.63%
OCF growth 3Y-27.78%
OCF growth 5Y9.25%